University of Central Florida

STARS
Faculty Bibliography 2000s

Faculty Bibliography

1-1-2008

Correlation between rpoB gene mutation in Mycobacterium avium
subspecies paratuberculosis and clinical rifabutin and rifampicin
resistance for treatment of Crohn's disease
Daniel R. Beckler
Sammer Elwasila
George Ghobrial
John F. Valentine
Saleh A. Naser

Find similar works at: https://stars.library.ucf.edu/facultybib2000
University of Central Florida Libraries http://library.ucf.edu
This Article is brought to you for free and open access by the Faculty Bibliography at STARS. It has been accepted for
inclusion in Faculty Bibliography 2000s by an authorized administrator of STARS. For more information, please
contact STARS@ucf.edu.

Recommended Citation
Beckler, Daniel R.; Elwasila, Sammer; Ghobrial, George; Valentine, John F.; and Naser, Saleh A., "Correlation
between rpoB gene mutation in Mycobacterium avium subspecies paratuberculosis and clinical rifabutin
and rifampicin resistance for treatment of Crohn's disease" (2008). Faculty Bibliography 2000s. 106.
https://stars.library.ucf.edu/facultybib2000/106

Online Submissions: wjg.wjgnet.com					
www.wjgnet.com
wjg@wjgnet.com

World J Gastroenterol 2008 May 7; 14(17): 2723-2730
World Journal of Gastroenterology ISSN 1007-9327
© 2008 WJG. All rights reserved.

BASIC RESEARCH

Correlation between rpoB gene mutation in Mycobacterium
avium subspecies paratuberculosis and clinical rifabutin and
rifampicin resistance for treatment of Crohn’s disease
Daniel R Beckler, Sammer Elwasila, George Ghobrial, John F Valentine, Saleh A Naser
Daniel R Beckler, Sammer Elwasila, George Ghobrial, Saleh
A Naser, Department of Molecular Biology and Microbiology,
Burnett School of Biomedical Sciences, Center for Biomolecular
Sciences, College of Medicine, University of Central Florida,
Florida, FL 32816, United States
John F Valentine, Department of Medicine, University of
Florida, Gainesville, Florida, FL 32810, United States
Author contributions: Beckler DR, Elwasila S, Ghobrial G,
Valentine JF, Naser SA contributed equally to the work; Beckler
DR, Elwasila S, and Ghobrial G participated in the experiments
design and the data collection; Valentine JF provided the
clinical samples and assisted in data interpretation; Naser SA
participated in research design, supervising the daily experiments,
interpretation of the data and editing the manuscript.
Supported by Grant RO1-AI51251-01 from NIH-NIAID
Correspondence to: Saleh A Naser, Professor, Department
of Molecular Biology and Microbiology, Burnett School of
Biomedical Sciences, College of Medicine, University of Central
Florida, 4000 Central Florida Blvd, Florida, FL 32816,
United States. nasers@mail.ucf.edu
Telephone: +1-407-823-0955 Fax: +1-407-823-0956
Received: December 20, 2007 Revised: March 14, 2008

selected mutation in MAP strain UCF5 resulted in the
generation of a new resistant strain (UCF5-RIF16r)
that possessed T1442C rpoB mutation and an MIC >
30 mg/L and > 10 mg/L for RIF and RFB respectively.
Sequencing of the entire rpoB gene in MAP strains
UCF4, 18, and UCF5-RIF16r revealed an rpoB mutation
A2284C further downstream of the 81 bp variable region
in UCF4, accounting for observed slight increase in MIC.
In addition, no other significant mutations were found in
strains 18 and UCF-RIF16r.
CONCLUSION: The data clearly illustrates that clinical
and in vitro -selected MAP mutants with rpoB mutations
result in resistance to RIF and RFB, and that a single
amino acid change in the beta subunit may have a
significant impact on RIF resistance. Unconventional drug
susceptibility testing such as our molecular approach will
be beneficial for evaluation of antibiotic effectiveness.
This molecular approach may also serve as a model for
other drugs used for treatment of MAP infections.
© 2008 WJG . All rights reserved.

Abstract
AIM: To investigate overlapping regions of the rpoB
gene previously involved with rifamycin resistance in M.
tuberculosis and seek correlation between rpoB mutations
in clinical MAP strains with susceptibility to RIF and RFB.
METHODS: We designed a molecular-based PCR method
for the evaluation of rifabutin (RFB) and rifampicin (RIF)
resistance based on probable determinant regions within
the rpoB gene of MAP, including the 81 bp variable
site located between nucleotides 1363 and 1443. The
minimum inhibitory concentration (MIC) for RIF was also
determined against 11 MAP isolates in attempt to seek
correlation with rpoB sequences.
RESULTS: We determined that MAP strain 18 had
an MIC of > 30 mg/L and ≤ 5 mg/L for RIF and RFB
respectively, and a significant and novel rpoB mutation
C1367T, compared to an MIC of ≤ 1.0 mg/L for both
drugs in the wild type MAP. The 30-fold increase in the
MIC was a direct result of the rpoB mutation C1367T,
which caused an amino acid change Thr456 to Ile456
in the drug’s binding site. In addition, MAP strain 185
contained five silent rpoB mutations and exhibited an
MIC comparable to the wild-type. Moreover, our in vitro
www.wjgnet.com
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INTRODUCTION
Crohn’s disease (CD) is an inflammatory bowel disease that
detrimentally affects the epithelial lining of the digestive
tract and presents with symptoms such as diarrhea, weight
loss, abdominal pain, and constipation[1]. Despite the gross
similarity of histological and pathological characteristics
between CD and the inflammatory intestinal disease found

2724

ISSN 1007-9327

CN 14-1219/R   

World J Gastroenterol

in cattle with Johne’s disease (JD), both diseases remain
distinct[1,2]. There is a strong debate currently between CD’s
potential autoimmune cause and its relation to bacteria,
and either concept has yet to be proven. Mycobacterium
avium subspecies paratuberculosis (MAP) is known to be the
causative agent of JD and has previously been implicated in
etiological studies of CD[2-8]. Available information regarding
MAP’s role in CD pathogenesis has promoted the ongoing
studies to continue investigating the relationship between
the MAP bacterium and the human bowel disease[3]. A most
recent report has shown that antibiotics including rifabutin
(RFB) is beneficial to CD patients despite the fact that the
clinical trial study met with a few shortcomings regarding
drug dosage, duration, and lack of MAP testing for the
participating subjects[9]. The latter is best detected using
PCR-based assays that amplify regions of the insertion
sequence IS900 as shown by many investigators[10-12].
RFB and rifampicin (RIF) are antibiotics that belong to
the rifamycin drug family and are very similar in chemical
structure. The function of these antibiotics are to inhibit
the growth of bacteria, specifically by binding to the beta
subunit of RNA polymerase through direct and indirect
amino acid interactions, and preventing the production of
nascent RNA transcripts[13]. The rpoB gene in prokaryotes
encodes the beta subunit, and mutations within this gene
result in a higher level of resistance to the rifamycin
antibiotics in several bacteria[14-19]. Moreover, mutations
within an 81 base pair region in rpoB spanning nucleotides
1276-1356 in M. tuberculosis have been shown to contain the
majority of alterations relating to rifamycin resistance[20]. In
addition, mutations at the beginning of rpoB are associated
with rifamycin resistance in some strains of M. tuberculosis.
However, these occurrences are not as prevalent as the
former[15,21].
Previous reports have shown that RFB may potentially
serve as a therapeutic agent for the treatment of CD[22-27],
and as an effective drug against MAP[28]. In addition, other
treatments such as anti-inflammatory agents have been
proved to relieve symptoms of CD [29]; however these
treatments are not as beneficial as antibiotic therapy[22]. As a
result, more attention has been focused on the possible use
of antibiotics as an alternative remedy. However, a screening
method for RIF and RFB resistant strains of MAP has yet
to be established. Therefore, as CD therapy becomes more
focused on antibiotics, it is essential to develop a method for
susceptibility testing in order to detect and monitor MAP
strains for RIF and RFB resistance.
Unlike other prokaryotes, MAP is very fastidious
and requires unusual in vitro growth conditions, including
the addition of Mycobactin J. Additionally, MAP cultured
from CD samples has shown to lack a cell wall, and
this characteristic is a major contributing factor to the
complexity of the bacteria’s primary isolation process[11,30,31].
Consequently, conventional drug susceptibility tests involving
MAP are not reliable and may result in inaccurate results.
Therefore, the challenges faced when working with this
bacterium must be counteracted via alternate approaches that
could potentially result in the exposition of significant data
in order to effectively treat MAP infections. In this study, we
adopted a molecular approach based on PCR amplification,
followed by nucleotide sequencing of regions within
www.wjgnet.com
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the rpoB gene of MAP. We attempted to investigate the
overlapping regions of the rpoB gene previously involved
with rifamycin resistance in M. tuberculosis. The ultimate goal
is to seek the correlation between rpoB mutations in clinical
MAP strains with susceptibility to RIF and RFB.

Materials and Methods
Bacterial strains and growth conditions
All clinical strains including UCF3, UCF4, UCF5, UCF7,
UCF8, MAP18, MAP185, and 61a were isolated in our
laboratory from clinical samples obtained from CD
patients[32]. Each MAP isolate was taken from different
patients; however the anatomical sources for each overlap.
For instance, each MAP isolate was isolated from their
corresponding anatomical sources of individual CD
patients: UCF3, UCF4, UCF8, 18, and 61a from the
ileal; UCF5 and UCF7 from ileocolonic tissue; and 185
from the mesenteric lymph node. These MAP strains
originated from surgical tissue samples obtained from
CD patients[32-34]. Cow2013 and Cow5 MAP strains were
recently isolated from ground beef samples from two
cattles with JD. Briefly, tissue samples were ground,
homogenized, decontaminated and then inoculated into
MGIT culture media with supplements including OADC,
Mycobactin J and PANTA as described previously[32].
All American type culture collection (ATCC) strains
were verified in our laboratory by biochemical and
molecular testing, including MAP strain 43 544, M. avium
subspecies avium 25 291, M. tuberculosis strain 25 177,
and M smegmatis strain 607. All cultures were subcultured
in 7H10 agar supplemented with oleic acid-albumindextrose-catalase (OADC) and Mycoabctin J. Plates were
incubated at 37℃ until visible colonies were observed.
Colonies from pure culture verified by Ziehl-Neelsen
acid fast stain and IS900-based PCR for MAP were used
to inoculate BACTEC 7H9 broth culture supplemented
with 500 µL OADC and 2.4 µmol/L Mycobactin J. Growth
index (GI) was read weekly until optimum growth index
was observed. The fresh culture was then used for drug
susceptibility testing and for molecular studies.
Minimum inhibitory concentration (MIC) measurement
MIC for RIF and RFB were determined against all microorganisms used for this study. Starting cultures with a GI
range of 500-600 were found optimal for inoculation.
The inoculum size for each Bactec bottle used in the drug
susceptibility study was approximately 1.0 × 105 CFUs.
Serial dilutions of RIF concentration ranging from 0
to 4 mg/L were evaluated against all micro-organisms.
MAP strains resistant to RIF > 1.0 mg/L were further
tested against RIF concentrations of 10, 20 and 30 mg/
L for MIC measurement. These MAP strains were also
evaluated against RFB at concentrations ranging from 0.0 to
10 mg/L, excluding UCF4. MAP wild type was included as a
control in each batch of analysis. Experiments were repeated
for confirmations. Micro-organisms other than MAP were
also evaluated for RIF concentrations ranging from 0.0
to 10.0 mg/L. The percentage of RIF or RFB inhibition
was used to determine the level of susceptibility for each
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Table 1 PCR primers used in this study
Primers
IS900
P90
P91
AV1
AV2
rpoB
Efox1
Fox1r
UCF1
UCF2
Fox1f
DBR
Knight1
Knight2
Ex1a
Ex2a
Ex3
Ex4
Ex5
Hrox1

Sequence (5' to 3')

Amplified
Amplicon
1
base pairs (bp) length (bp)

GTTCGGGGCCGTCGCTTAGG
GAGGTCGATCGCCCACGTGA
ATGTGGTTGCTGTGTTGGATGG
CCGCCGCAATCAACTCCAG

22-421

400

77-384

308

TTGCCGGCCGAACCGACACA
TGTCGACGTCGAACTCCAGC
TCGATGTCGCTGTCTTTCTC
GCTCGGTGATCTGCTCGTTG
CGGTGTTCATGGGTGACTTC
GTAGTGGGACGGGTGCACGTC
ACCACTTCGGCAACCGCCGG
ACTCGACCTCGCCCGCCTTG
AAGGTGGTCGACGGCGTGGT
GATCTCGTGCTCCTCGATGT
ACGAGGACGCGATCATCCT
TCGACACGATCTGGTTCGGC
GAACATCGACGGCAATCCCG
TCCGTCGAGGACCTGGCTTAA

1-721

721

373-820

448

521-1509

989

1191-1777

587

1621-2340

720

2261-2980

720

2901-3597

697

1

Numbers represent nucleotide positions within each gene of MAP.

concentration of antibiotics as follows: % Inhibition = 1
minus (GI of Bactec culture without drug minus GI of
Bactec culture with drug)/GI of Bactec culture without
drug). The MIC was also determined for each bacterial
sample, and was defined as the minimum concentration of
antibiotics that induced inhibition of growth by 90%.
Microbial genomic DNA extraction, nested PCR and
nucleotide sequencing
Extraction of genomic DNA from mycobacterial isolates
was performed for verification of the presence of the
IS900 gene and for analysis of rpoB gene sequence. The
DNA extraction, purification and quantification were
performed as described previously[11]. Nested PCR for
IS900 amplification was performed using the primers
p90/91 and AV1/AV2 as listed in Table 1[11]. The size of
amplified product was determined on 2% agarose gel.
Appropriate negative controls for PCR consisting of
sterile TE buffer or sterile water in place of the DNA
template were used in parallel with each round of PCR
preparation. Positive MAP DNA from strain ATCC 43015
was prepared independently and added to PCR tubes at a
different facility using separate supplies.
Unlike the nested IS900-based PCR assay, only one
round of PCR assays was developed for amplification of
two different regions of the rpoB gene. Therefore, one
PCR reaction contained the UCF1/UCF2 primers for
amplification of 448 bp whereas the second PCR reaction
contained the Knight1/Knight2 primers for amplification
of 587 bp. The ingredients and protocol conditions of the
rpoB-based PCR assays were as described previously[11].
Table 2 lists the nucleotide sequence for all primers used
in this study. Each PCR product was purified from agarose
using the Purelink Quick Gel Extraction Kit following the
procedure described by the manufacturer (Invitrogen).
Purified DNA was then quantitated and subjected to

nucleotide sequencing. The latter was performed using
the GenomeLab DTCS-Quick Start Kit following the
manufacturer’s instructions (Beckman Coulter). Both
DNA strands were sequenced for each PCR product using
appropriate nucleotide primers at the Biomolecular Science
Center DNA Sequencing Core Facility at the University of
Central Florida. BLAST analysis was performed using the
Pubmed.gov database, and the rpoB sequence from MAP
strain K-10[35] was used as our reference wildtype control
sequence for comparison purposes.
In vitro selected RIF-MAP mutant
An RIF resistant MAP mutant (UCF5-RIF16r) was selected
through the generation of rpoB mutation via adaptive
resistance in the presence of antibiotics. This was performed
by exposing our wild-type MAP strain UCF5 to increase the
concentrations of RIF ranging from 1 to 16 mg/L. Initially,
MAP strain UCF5 was inoculated into a BACTEC bottle
containing 1 mg/L RIF. Following incubation, the surviving
MAP cells were sub-cultured into a new BACTEC bottle
with double RIF concentrations. The process was repeated
several times until a new MAP strain (UCF5-RIF16r) was
selected that was able to survive in the presence of 16 mg/L
of RIF. This new resistant strain was then tested for MIC
against RIF and RFB and investigated for possible rpoB
mutations as described earlier.

Results
Identification of MAP
Genomic DNA from all bacterial isolates was subjected
to IS900-based PCR in order to confirm the identity of
all MAP strains. This procedure involved two rounds of
PCR, using p90/91 primers in the first round to amplify
a 400 bp sequence. The use of AV1/AV2 in the second
round of PCR amplified a 308 bp sequence and provided
exceptional sensitivity and enhanced specificity for the
confirmation of MAP. As expected, all 11 MAP isolates
were confirmed for the presence of IS900. In addition,
M. avium subspecies avium, M. smegmatis and M tuberculosis
displayed negative results for the presence of the IS900.
rpoB amplification and sequence analysis
Following the IS900 PCR analysis, genomic DNA from
each identified MAP strain was used as template for PCR
employing rpoB primers (Table 1). Amplification of rpoB
sequences enabled the possibility for amplicon purification,
sequencing, and subsequently BLAST analysis. The use of
primers UCF1/UCF2 and Knight1/Knight2 enabled the
amplification of two regions of the rpoB gene of MAP.
These regions overlapped similar sequences in the rpoB
gene of M. tuberculosis previously associated with rifamycin
resistance. Moreover, PCR with Knight1/Knight2 primers
amplified a sequence that harbored the 81 bp variable
site 1363-1443, a highly probable determinant region for
rifamycin resistance in closely related bacteria. Amplicons
from both regions of the rpoB gene were obtained by
successful PCR.
Nucleotide sequencing of both rpoB regions for all
MAP strains was performed for both forward and reverse
primer reactions to exclude any possible errors in the data.
www.wjgnet.com
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Table 2 rpoB and susceptibility data for all micro-organization
Microorganism

Strain

MAP
MAP
MAP
MAP
MAP
MAP
MAP
MAP
MAP
MAP
MAP
M avium subspecies. avium5
M tuberculosis5
M smegmatis5
UCF5-RIF16r

ATCC43544
UCF3
UCF4
UCF5
UCF7
UCF8
18
185
Cow2013
Cow5
61a
ATCC25291
ATCC25177
ATCC607
Modified UCF5

RIF MIC (mg/L) RFB MIC (mg/L)
≤ 1.0
≤ 1.0
≤ 2.5
≤ 1.0
≤ 1.0
≤ 1.0
≥ 30
≤ 4.0
≤ 1.0
≤ 1.0
≤ 1.0
≤ 1.0
≤ 1.0
≥ 9.0
≥ 30

≤ 1.0

≤ 5.0
≤ 1.0

≥ 10

1

2

Inhib. at 1 mg/L of RIF (%)
91 ± 0.71
94 ± 2.83
79 ± 7.07
92.5 ± 0.71
88 ± 5.66
90 ± 1.41
42 ± 1.00
61 ± 7.07
95 ± 1.41
96.5 ± 0.71
90 ± 3.54
90 ± 1.41
92 ± 1.41
6.6 ± 1.7
32 ± 1.41

rpoB BLAST result

3

Amino acid change

WT
WT
A2284C
WT
WT
WT
C1367T
Silent
WT
WT
WT

NC
NC
N762H
NC
NC
NC
T456I
NC
NC
NC
NC

T1442C

L481P

4

1

Limited investigation involving MAP18, MAP185, and UCF5-RIF16r; 2Values are expressed as mean ± SD; 3Wild type (WT) indicates identical investigated
rpoB sequence compared to MAP K-10 strain, and differentially expressed rpoB mutations are indicated; 4Amino acid positions correspond to MAP strain K-10
numbering system from Li et al 2005, and the alteration is indicated with single letter amino acid codes and the corresponding codon number. NC corresponds to
no change in beta subunit sequence based on investigated rpoB regions; 5rpoB sequence was not investigated.

Furthermore, sequence data was reported as completely
accurate upon the confirmation of error-free reactions. In
addition, rpoB sequences for all MAP strains were compared
through BLAST analysis using MAP strain K-10 as a
reference strain, and amino acid positions were numbered
based on MAP strain K-10. The numbering system for
E. coli provided by Ramaswamy et al in 1998 was also used in
order to avoid discrimination of our observed results, and to
enable a more general comparison of previously published
data relevant to other mycobacterial species.
Sequence analysis found identical, or wild-type (WT), and
non-identical sequences. MAP strains consisting of the latter
were further characterized for silent mutations with no effect
on amino acid expression, or mutations that differentially
expressed the amino acid sequence of the beta subunit. Of
the 11 MAP clinical isolates, 9 consisted of no rpoB mutation
in the two regions initially investigated (Table 2). However,
two MAP strains possessed rpoB mutations, and these
consisted of MAP strain 18 and 185. The rpoB mutations for
MAP strain 18 included C1367T and T1375C. The C1367T
mutation had significant amino acid changes from Thr456
to Ile456 in the beta subunit of RNA polymerase, which
corresponded to a Ser508 to Ile508 change according to the
E. coli numbering system. To our knowledge, this amino acid
change was considered novel as well as indicative of RIF and
RFB resistance. The T1375C mutation had no effect on the
beta subunit, and was, therefore, characterized as being silent
(Table 2). Alternatively, MAP strain 185, which was also
isolated in our laboratory from the surgical mesenteric lymph
node tissues of a CD patient, showed a total of five rpoB
mutations including T534C, T795C, C1335A, T1375C, and
C1578T (Table 2). None of the five mutations altered the
amino acid sequence in the beta subunit, and consequently
were also termed silent. The effects of all rpoB mutations
on RIF and RFB susceptibility were investigated following
sequence analysis.
Effect of rpoB mutations on MIC
Correlation between rpoB sequence analysis and inhibitory
www.wjgnet.com

growth rates of RIF was assessed for all MAP strains.
Initially, we tested all MAP strains in the presence of
1 mg/L RIF for comparison purposes (Table 2). This
concentration was found to be the MIC of our wildtype control. Hence, our initial susceptibility test was to
screen for suspicious growth characteristics against this
concentration of RIF. Of the bacterial isolates studied,
8 MAP strains including ATCC43544 (control), UCF3,
UCF5, UCF7-8, 61a, Cow2013, Cow5, and two nonMAP controls including M. tuberculosis and M. avium
subspecies avium had an MIC ≤ 1.0 mg/L RIF (Table 2).
In addition, there were no observed rpoB mutations in
these 8 RIF susceptible MAP strains. The MIC for RIF of
the remaining MAP strains 18, 185, UCF4, and M. smegmatis
was determined as ≥ 30, ≤ 4.0, ≤ 2.5 and ≥ 9.0 mg/L,
respectively (Table 2). Furthermore, MAP strains 18 and
185 had rpoB mutations in the 81 bp variable region as
discussed earlier, and MAP strain UCF4 had no rpoB
mutations within the two regions. Despite the lack of
rpoB mutations, M. smegmatis had MIC of ≥ 9 mg/L
RIF. RIF-resistance MAP strains were also evaluated
for susceptibility against RFB, a more potent rifamycin
antibiotic. Interestingly, the MIC for RFB against MAP
strain 18 and 185 was ≤ 5.0 mg/L and ≤ 1.0mg/L,
respectively (Table 2). The MIC values for the drugs
against all microorganisms are listed in Table 2.
Correlation between selected rpoB resistant mutation and
MIC in UCF5-RIF16r
An RIF resistant MAP strain, termed UCF5-RIF16r,
was selected via culturing wild-type parent strain UCF5
in increasing concentrations of RIF over an extended
time period. Specifically, this was accomplished by
exposing parent strain UCF5 to a five-fold increase in RIF
concentrations over approximately 2 mo. UCF5-RIF16r
was then maintained in cultures with > 16.0 mg/L RIF.
Genomic DNA was then extracted and followed by IS900nested PCR and rpoB-based PCR analysis. Consequently,
the newly selected resistant strain was confirmed for the
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Control
UCF3
UCF4
UCF5
UCF7
UCF8
  MAP18
Cow2013
  Cow5
61a
UCF5-RIF16r

Figure 1 Sequence alignment of 81 bp region in rpoB gene of MAP. The region overlaps the 81 bp rifamycin resistant determinant region within M. tuberculosis. For MAP,
this sequence is harbored in the region amplified by primers Knight1/Knight2. Differentially expressed rpoB mutations are indicated for MAP strains 18 and UCF5-RIF16r.
Base pairs and amino acids range from 1363-1443 and 456-481. Numbering of amino acids correspond to MAP strain K-10 beta subunit. Dots correspond to homologous
bases and specific nucleotides are underlined in the control sequence. MAP strain 185 is excluded from diagram.

presence of IS900, and both regions of the rpoB gene
were analyzed. We detected a single nucleotide rpoB
mutation T1442C, which caused a differentially expressed
amino acid from Leu481 to Pro481 in the beta subunit
of RNA polymerase, which corresponded to a Leu533
to Pro533 change according to the E. coli numbering
system (Table 2). Furthermore, the rpoB mutation was
located within the 81 bp variable region, and the effect of
the selected mutation on susceptibility to RIF was then
investigated. The MIC for UCF5-RIF16r against RIF and
RFB was ≥ 30 mg/L and ≥ 10 mg/L, respectively.
Sequencing rpoB genes in MAP strains 18, UCF4 and
UCF5-RIF16r
We attempted to sequence the entire 3.6 kb rpoB gene
in order to determine the source of the variable increase
in MIC for RIF against MAP strain UCF4, and to detect
any other possible rpoB mutations leading to amino
acid alterations in strains 18 and UCF5-RIF16r. We
designed additional primers for PCR amplification of
sequences outside that amplified by primers UCF1/UCF2
and Knight1/Knight2 (Table 1). After successful PCR
amplification of these regions, nucleotide sequencing was
performed. Through BLAST analysis, we found a significant
rpoB mutation further downstream of the 81 bp variable
region in MAP strain UCF4. Specifically, an A2284C
mutation occurred within the region amplified by primers
Ex1a/Ex2a. This mutation resulted in an Asn762 to His762
amino acid change, leading to a possible explanation for
the higher MIC for RIF compared to our wild-type control
strain 43544. No other rpoB mutations leading to amino
acid changes were observed in MAP strains 18, UCF5RIF16r, and UCF4. After obtaining collective sequence
information for all MAP isolates, we aligned the 81 bp
variable region to display the location of each mutation
amino acid change that correlated with a high level of RIF
resistance (Figure 1).
Detection of rpoB in PBMNC infected with MAP
To show the potential for sequence analysis in the rpoB
gene of MAP clinical isolates in correspondence with RIF
and RFB resistance, we contaminated human PBMNC
with 1.0 × 10 3 CFU of MAP strain 18. Prokaryotic

genomic DNA was then extracted from the blood mixture,
followed by IS900-PCR and rpoB-based PCR analysis. As
expected, our protocol detected MAP in the blood sample
and successfully amplified both regions of the rpoB gene
of MAP (data not shown). The nucleotide sequence was
then analyzed for the possible prediction of susceptibility
to RIF or RFB.

DISCUSSION
The main purpose of our study was (1) to characterize
MAP’s potential for developing RFB and RIF resistance,
(2) associate RFB and RIF resistance with mutations in the
rpoB gene of MAP, and (3) provide an effective protocol
for detecting resistant mutations in MAP strains linked
to CD. Despite the fact that M. smegmatis is known to be
naturally resistant to rifamycins without rpoB mutations[36],
microorganisms such as M. avium spp. avium, E. coli, H pylori,
S. aureus and M. kansasii have laid the foundation for this
association[14,16,18,19,21,37]. Moreover, various strains of closely
related M. tuberculosis have set a fine trend for rifamycin
resistance, as seen through rpoB mutations[6,17,21,38-46]. Our
goal was to discover this trend in MAP, and develop an
effective method for analyzing RFB and RIF resistance in
the bacterium through rpoB-based PCR analysis.
Unlike M. tuberculosis and members of the M. avium
complex (MAC), MAP is a fastidious micro-organism
and requires prolonged incubation time. Consequently,
conventional drug susceptibility testing against MAP strains
is ineffective, thus leading us to develop an alternative
method for determining drug resistance in MAP.
The UCF1/UCF2 and Knight1/Knight2 rpoB primers
enabled the successful amplification and sequencing
of two probable RFB and RIF resistant determinant
regions (Table 1). These regions overlap similar sequences
in the rpoB gene of M. tuberculosis that have displayed
mutations upon rifamycin resistance, including the 81 bp
region 1276-1356 within cluster I, and a region further
located in the upstream of the beginning of rpoB[6,15,20].
Consequently, our determinant regions of interest in the
rpoB gene of MAP were concluded based on the available
information for closely related bacteria.
All MAP isolates were identified through an IS900
nested PCR reaction and each was investigated for rpoB
www.wjgnet.com

2728

ISSN 1007-9327

CN 14-1219/R   

World J Gastroenterol

sequences and susceptibility tests against RIF. Those
isolates suspected to be RIF resistant based on high MIC
results were subjected to susceptibility tests against RFB.
Consequently, the control, MAP strain 18 and UCF5RIF16r were included in a RFB inhibition test. MAP strain
185 was also included in the RFB test due to the strain’s
suspicious susceptibility against RIF. Unlike RIF, RFB
is not commercially available for laboratory use. Hence,
information based on antibiotic resistance in our study was
subjective mainly for RIF.
Our significant findings included the discovery of
rpoB mutations within MAP strains 18, UCF5-RIF16r,
and UCF4. Both strains 18 and UCF5-RIF16r showed a
significant increase in the level of resistance due to amino
acid alterations within the binding site of RIF. Moreover,
upon our additional sequencing of the entire 3.6 kb rpoB
gene for all three MAP strains along with a control, a
significant rpoB mutation A2284C was uncovered leading
to an Asn762 to His762 amino acid change in the beta
subunit. These results justified the minor increase in MIC
against RIF for strain UCF4. In addition, the complete
sequencing of the rpoB in MAP strains 18 and UCF5RIF16 proved that no additional rpoB mutations leading
to an amino acid change were present, confirming the
correlation between detected mutations and increased
MIC in these micro-organisms. The finding illustrates that
a single amino acid change in the rpoB gene of MAP may
result in an increased level of resistance to RIF, which may
have a significant clinical impact, specifically when the
amino acid alterations occur within the drug’s binding site.
Overall, our results display a novel rpoB mutation,
C1367T, in MAP strain 18 not previously reported
in the literature including rpoB studies in E. coli and
M. tuberculosis. In addition, the A2284C rpoB mutation
discovered in MAP strain UCF4 was also novel to our
knowledge; however this mutation did not influence RIF
resistance significantly compared to MAP strains 18 and
UCF5-RIF16r. A possible explanation for this observation
is that the mutation in strain UCF4 was located distant
from the drug binding site. The selected rpoB mutation
in strain UCF5-RIF16r has previously been reported
to occur in M. tuberculosis as well as in E. coli [13]. More
significantly, Leu481 in the beta subunit of MAP overlaps
that of Leu413 in Thermus aquaticus, and this amino acid
has been reported to make direct contacts with RIF in its
bound state through Vanderwaals interactions[13]. Hence,
the selected change from Leu481 to Pro481 in MAP strain
UCF5-RIF16r may have affected the direct interaction
between the beta subunit and the drug.
The rationale in selecting the RIF resistant mutant
UCF5-RIF16r was to determine the potential for MAP
to evolve adaptive resistance to RIF, and the location
of the rpoB mutation that accounted for the resistance.
This data, combined with our analysis of MAP strain 18,
showed the potential for MAP to evolve resistance to RFB
and RIF in vivo and in vitro through mutations in the 81 bp
variable region. Collectively, after analyzing the resistance
characteristics for MAP strain 18 and UCF5-RIF16r, we
considered the rpoB 81 bp variable regions to be the most
significant for determining resistant mutations for RFB
and RIF.
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MAP strain 185 consisting of five silent mutations within
rpoB was not considered significant because they did not
alter the beta subunit sequence. Moreover, we encountered
unusual PCR results and difficulties in extracting genomic
DNA from strain 185; therefore, we were unable to sequence
its entire rpoB gene and account for the slight resistance to
RIF. Hence, the mechanism of the partial resistance against
RIF for this strain remained undetermined.
Our rpoB-based protocol on human blood mixed
with MAP was accomplished through contaminating
normal human blood with MAP strain 18, and extracting
bacterial DNA directly from the blood mixture. As a
result, a sufficient amount of bacterial genomic DNA was
obtained for successful amplification of our regions of
interest within rpoB (data not shown). The purpose of this
approach was to assess the effectiveness of our protocol
on CD patient blood.
Information regarding patient history may explain a
rationale for the observed results. Ironically, the patients’
medical history indicated that none of them was on antiMAP treatment. Instead these patients had received a
variety of anti-inflammatory and immunosuppressants.
However, alarming new reports suggest that some of
these drugs may contain antimicrobial activity, especially
when tested against few strains of MAP [47]. Hence, it
is inconclusive to rule out the possibility of antibiotic
resistance development via alternative drugs.
In conclusion, through the application of our protocol
on CD patient samples, we may assist in the determination
of RFB and RIF susceptible MAP strains for the treatment
of CD. The inconclusive results from the recent Australian
clinical trial using RFB, calrithromycin and clofazamine
for treatment of patients with CD[9] suggested either the
absence of MAP or the presence of drug resistance MAP
in non-responders. Therefore, detection of drug resistance
in pathogens like MAP is now necessary. Our protocol may
address the rationale for MAP resistance to RFB in these
patients. Based upon the in vitro selection of a RFB and RIF
resistant MAP strain (UCF5-RIF16r), it is likely that this
trend occurs in vivo, as supported by the data from MAP
strain 18. Furthermore, as RFB is applied more towards
the treatment of CD, our protocol will be of utmost
significance for the optimization of CD treatment with
related antibiotics.
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